Retina Synthesis

147 Folgen

1. Strategies for Treatment Pauses in Neovascular AMD

   Vom: 2.2.2023
2. Gene Therapy of Inherited Retinal Diseases

   Vom: 26.1.2023
3. Suprachoroidal Tyrosinase Therapy of Neovascular AMD

   Vom: 12.1.2023
4. KSI-301 (tarcocimab tedromer) therapy of Retinal Vein Occlusion

   Vom: 5.1.2023
5. The Efficacy of Avacincaptad Pegol in Treatment of Geographic Atrophy: Gather 1 & 2 Study Results

   Vom: 15.12.2022
6. En Face OCT, Intermediate AMD, and Georgraphic Atrophy

   Vom: 8.12.2022
7. Safety of Pegcetacoplan in the 24 month Derby and Oaks Studies

   Vom: 1.12.2022
8. Predominantly Peripheral Lesions on Ultra-Wide field Imaging & Risk of DR Worsening Over Time

   Vom: 17.11.2022
9. 10 Year Retrospective Review of a PHP Device for Early Detection of Neovascular AMD

   Vom: 10.11.2022
10. Current Therapy for Venous Occlusive Disease and a Clinical Trial Involving Stem Cell Therapy for CRVO

    Vom: 27.10.2022
11. Senolytic Therapy for Diabetic Macular Edema and Neovascular AMD

    Vom: 20.10.2022
12. Assessment of Geographic Atrophy Lesion Progression in the Phase 3 Oaks and Derby Trials

    Vom: 13.10.2022
13. The Role of the Clinician in Promoting Innovation

    Vom: 6.10.2022
14. The DAVIO Study: 12 Month Results

    Vom: 22.9.2022
15. Treat and Extend Therapy of Diabetic Macular Edema

    Vom: 15.9.2022
16. Prophylactic IOP Lowering Measures in Anti-VEGF Injections: A Meta-Analysis

    Vom: 8.9.2022
17. Real World Efficacy, Durability and Safety of Faricimab

    Vom: 1.9.2022
18. New Treatments for Radiation Retinopathy

    Vom: 25.8.2022
19. Gene Therapy of Inherited Retinal Diseases

    Vom: 18.8.2022
20. RNA Anti Sense Therapy for Geographic Atrophy

    Vom: 11.8.2022